Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00433966 · ClinicalTrials.gov registry record · Phase 3
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
A Phase 3 study, sponsored by Cardiovascular Research Foundation, New York.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,602
- Enrollment target
NCT00433966 is a Phase 3 study that has completed, run by Cardiovascular Research Foundation, New York. The registered enrollment target is 3,602 participants.
The verdict
NCT00433966, a Phase 3 study, has completed, sponsored by Cardiovascular Research Foundation, New York.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,602 participants
- Enrollment target
Study Summary
The primary objectives of the trial are: 1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing a primary angioplasty strategy. 2. To establish the safety and efficacy of the slow rate release paclitaxel-eluting TAXUS™ stent compared to an otherwise identical uncoated bare metal EXPRESS2™ stent.
Interventions
- DRUG Bivalirudin
- DRUG Unfractionated heparin
- DEVICE Bare metal stent
- DEVICE Paclitaxel-eluting stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,602 participants |
| Start Date | 2005-03 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00433966
The ClinicalTrials.gov registry entry for NCT00433966 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,602 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardiovascular Research Foundation, New York, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bivalirudin is the first listed.
NCT00433966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00433966 about?
NCT00433966 is a clinical study titled "Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction". The primary objectives of the trial are: 1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing a primary angioplasty strateg...
What is the current status of trial NCT00433966?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,602 participants. The study started on 2005-03. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00433966?
The interventions under investigation include: Bivalirudin (DRUG), Unfractionated heparin (DRUG), Bare metal stent (DEVICE), Paclitaxel-eluting stent (DEVICE).
Who is sponsoring clinical trial NCT00433966?
This trial is sponsored by Cardiovascular Research Foundation, New York, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.